Published in Pak J Med Sci on July 04, 2016
Hyperglycemic crises in adult patients with diabetes. Diabetes Care (2009) 6.01
SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab (2015) 3.11
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab (2011) 3.00
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care (2013) 2.89
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med (2015) 2.85
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia (2013) 2.67
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract (2013) 2.09
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995) (2013) 1.97
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care (2014) 1.86
SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol (2015) 1.56
Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient. Case Rep Endocrinol (2015) 1.00
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. Curr Diab Rep (2010) 0.87